Effects of Empagliflozin on Arterial Stiffness in Veterans With Obesity Aged 30 to 60

What this Trial Is About

Researchers are evaluating the effects of empagliflozin, a medication that inhibits SGLT2, on arterial stiffness in Veterans with obesity. This randomized, double-blinded, placebo-controlled Phase 2 trial aims to understand how 12 weeks of empagliflozin treatment impacts arterial health compared to a placebo. The study will recruit 50 Veterans aged 30 to 60 years with a body mass index BMI between 30 and 45 kgm2 who show evidence of arterial stiffening. Participants will be randomly assigned to receive either 10 mg of empagliflozin daily or a matching placebo for 12 weeks. The trial involves two groups one receiving the active drug and the other receiving placebo tablets, both taken once daily. This treatment period will be closely monitored to assess the medications impact on arterial stiffness. During the study, participants will undergo assessments of carotid-femoral pulse wave velocity cfPWV at baseline, week 4, week 8, and week 12 to measure changes in arterial stiffness. Researchers will monitor safety and adherence throughout the trial. The total participation lasts about 12 weeks, during which various health evaluations will be conducted to gauge the effects of the treatment on vascular health.

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity